merck & co. - Search News

Weak 2025 Guidance Mangles Merck Stock Today

Insider Monkey on MSN · 16h

Merck & Co., Inc. (NYSE:MRK) Q4 2024 Earnings Call Transcript

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 EPS, expectations were $1.85. Operator: Thank you for standing by. Welcome to the Merck & Company Q4 Sales and Earnings Conference Call.

Business Insider · 1d

MRK Earnings: Weak 2025 Guidance Mangles Merck Stock Today

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted

The Wall Street Journal on MSN · 1d

Merck Earnings Rise; 2025 Outlook Hits Shares

Merck swung to a quarterly profit as sales grew to beat Wall Street’s estimates, although the drug company’s outlook for 2025 and a slide in sales of its HPV vaccine hit shares.

China, Merck and Gardasil

Hosted on MSN · 1d

Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.

FiercePharma · 1d

Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country. | The recent decline of Merck & Co.

BioPharma Dive · 1d

Merck shares tumble as company pauses Gardasil shipments to China

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

8h

Merck: Don't Fight The Tape, How Low Can It Go?

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.

2don MSN

Jim Cramer on Merck & Co., Inc. (MRK): ‘I Bet The Numbers Will Be Good, But There Are Other Issues’

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

12h

Analysts Defend Merck Amid Investor Concerns Over Weak Guidance

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

1d

Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

17hon MSN

Merck Is Suffering From a Classic Pharma Problem

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

18h

Citi Remains a Buy on Merck & Company (MRK)

Citi analyst Geoff Meacham maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of $115.00. The ...

Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

1d

Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential

Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results